13F Holdings
中文EN

CLNN Clene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1822791 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-47.7%
TTM net income YoY20.4%
TTM EPS YoY—
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—

Margins

Gross margin79.5%
Operating margin-9,676.3%
Net margin-11,520.5%
FCF margin-6,240.1%
EBITDA margin-9,195.3%

Returns

ROE-1,738.4%
ROA-98.9%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets132.4%
Debt / equity—
Current ratio1.57x
Interest coverage-8.14x

Cash quality & payout

Operating cash flow / net income0.54x
Accruals ratio-45.4%
Payout ratio—
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$200,000$342,000$654,000$473,000$723,000
Cost of revenue$43,000$70,000$121,000$26,000$289,000
Gross profit$157,000$272,000$533,000$447,000$434,000
R&D expense$14.01M$20.06M$26.66M$31.92M$28.42M
SG&A expense$9.23M$13.31M$14.42M$16.94M$22.00M
Operating income-$23.08M-$33.09M-$40.54M-$48.41M-$49.98M
Interest expense$2.68M$4.06M$4.56M$3.30M$870,000
Pretax income-$26.17M-$39.40M-$49.50M-$29.92M-$10.17M
Income tax$0$0$0$0-$428,000
Net income-$26.17M-$39.40M-$49.50M-$29.92M-$9.74M
EBITDA-$21.59M-$31.45M-$38.84M-$47.39M-$49.02M
EPS (basic)-2.65-5.67-9.43-0.46-0.16
EPS (diluted)————-0.16
Weighted avg. shares (diluted)————61.56M
Banking
Net interest income———-$3.30M-$870,000
Balance sheet
Cash & equivalents$5.19M$12.15M$28.82M$18.33M$50.29M
Short-term investments—$0$6.18M$4.98M$0
Receivables$0$64,000$143,000$189,000$49,000
Inventory$37,000$68,000$37,000$43,000$41,000
Current assets$8.98M$16.16M$38.85M$29.20M$54.58M
PP&E, net$6.02M$7.48M$9.26M$10.64M$5.17M
Total assets$18.13M$27.34M$52.34M$44.49M$63.06M
Current liabilities$10.78M$10.29M$25.33M$13.86M$6.03M
Long-term debt$17.79M————
Total debt$17.79M————
Total liabilities$35.72M$36.19M$38.95M$41.26M$50.47M
Shareholders' equity-$17.59M-$8.86M$13.39M$3.24M$12.60M
Net debt$12.60M————
Shares outstanding10.85M8.09M6.42M74.76M62.31M
Cash flow statement
Operating cash flow-$18.55M-$21.33M-$30.17M-$39.01M-$34.62M
Capital expenditure$39,000$15,000$330,000$5.18M$1.33M
Free cash flow-$18.59M-$21.34M-$30.50M-$44.19M-$35.96M
Investing cash flow-$39,000$6.32M-$1.50M-$10.16M-$1.33M
Financing cash flow$11.52M-$1.53M$42.16M$17.25M$27.11M
Depreciation & amortization$1.50M$1.65M$1.71M$1.02M$955,000
Stock-based compensation$6.38M$7.95M$9.12M$8.51M$12.38M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.